تداخلهای دارویی
Liposomal doxorubicin + Trastuzumab
شدت: شدید
Liposomal doxorubicin and Trastuzumab: major interaction.
آخرین بهروزرسانی
ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصهای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمیشود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.
محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.
خلاصه
Trastuzumab can cause cardiomyopathy and left ventricular dysfunction, and the risk is markedly higher when it follows or is combined with anthracyclines. Liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, but additive cardiac injury remains a concern.
معنای این تداخل به زبان ساده
Liposomal doxorubicin and Trastuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Liposomal doxorubicin belongs to Oncology; Trastuzumab belongs to Oncology.
چرا رخ میدهد
Additive cardiotoxicity: anthracycline myocyte injury combined with HER2 pathway inhibition impairing cardiomyocyte repair.
اقدام لازم
Assess LVEF before and periodically during therapy, and avoid concurrent use outside carefully monitored settings. Hold trastuzumab or stop the anthracycline if LVEF falls significantly or heart failure symptoms appear.
از داروساز چه بپرسید
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
ویژه اعضای Pro+
باز کردن کل صفحه
یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا توصیههای کامل مدیریت Liposomal doxorubicin و Trastuzumab، یادداشتهای تکمیلی، جزئیات شواهد و بررسیکننده تداخل برای کل نسخه را باز کنید.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Pro+ را ۱۴ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.
تداخلات دیگر Liposomal doxorubicin
تداخلات دیگر Trastuzumab
پرسشهای متداول
Can I take Liposomal doxorubicin with Trastuzumab?
MediHelp rates the interaction as major. Liposomal doxorubicin and Trastuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Trastuzumab can cause cardiomyopathy and left ventricular dysfunction, and the risk is markedly higher when it follows or is combined with anthracyclines. Liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, but additive cardiac injury remains a concern.
How serious is the interaction between Liposomal doxorubicin and Trastuzumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Assess LVEF before and periodically during therapy, and avoid concurrent use outside carefully monitored settings. Hold trastuzumab or stop the anthracycline if LVEF falls significantly or heart failure symptoms appear.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
تکنگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp
مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.